Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

NCT03817320 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT03817320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03817320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 12, 2019
Completion date
June 30, 2025
Enrollment
24 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

all, childhood, lymphoblastic leukemia, acute, childhood, lymphoblastic lymphoma, childhood